Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonard Saltz

Showing results (61-70 of 167) with videos related to

Pageof 17
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|June 14, 2014
False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancerAnya Litvak, Andrea Cercek, Neil Segal, et al.
Epigenetics|May 8, 2024
Evaluating the utility of <i>ZNF331</i> promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)Elizabeth S Nakasone, Tyler J Zemla, Ming Yu, et al.
Gastrointestinal Cancer Research : GCR|October 23, 2013
Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic CancerHaifa Dbouk, Hana Ajouz, Ali Shamseddine, et al.
JCO Oncology Practice|June 20, 2022
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine TumorsNitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 2008
ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancerW Warren Suh, A William Blackstock, Joseph Herman, et al.
The Oncologist|April 27, 2005
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forumRomán Pérez-Soler, Jean Pierre Delord, Allan Halpern, et al.
Gastrointestinal Cancer Research : GCR|August 13, 2013
A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasisCarla Hajj, Karyn Goodman, David Kelsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumorsGary K Schwartz, Eileen O'Reilly, David Ilson, et al.
Current Problems in Cancer|June 15, 2010
ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentationJoseph Herman, Wells Messersmith, W Warren Suh, et al.
Pageof 17

Showing results (61-70 of 167) with videos related to

Sort By:
Pageof 17
Journal of the National Comprehensive Cancer Network : JNCCN|June 14, 2014
False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancerAnya Litvak, Andrea Cercek, Neil Segal, et al.
Epigenetics|May 8, 2024
Evaluating the utility of <i>ZNF331</i> promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)Elizabeth S Nakasone, Tyler J Zemla, Ming Yu, et al.
Gastrointestinal Cancer Research : GCR|October 23, 2013
Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic CancerHaifa Dbouk, Hana Ajouz, Ali Shamseddine, et al.
JCO Oncology Practice|June 20, 2022
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine TumorsNitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 2008
ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancerW Warren Suh, A William Blackstock, Joseph Herman, et al.
The Oncologist|April 27, 2005
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forumRomán Pérez-Soler, Jean Pierre Delord, Allan Halpern, et al.
Gastrointestinal Cancer Research : GCR|August 13, 2013
A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasisCarla Hajj, Karyn Goodman, David Kelsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumorsGary K Schwartz, Eileen O'Reilly, David Ilson, et al.
Current Problems in Cancer|June 15, 2010
ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentationJoseph Herman, Wells Messersmith, W Warren Suh, et al.
Pageof 17